No description
-
2018 (v1)PublicationUploaded on: April 14, 2023
-
2022 (v1)Publication
Endocrine therapy represents the gold standard for the adjuvant treatment of luminal-like early breast cancer, but its personalization is still a major point of debate. To define the most appropriate therapeutic strategy, both the patient's menopausal status at the moment of diagnosis and the individual risk of disease recurrence should be...
Uploaded on: January 31, 2024 -
2023 (v1)Publication
No description
Uploaded on: February 4, 2024 -
2017 (v1)Publication
Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancer patients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancer patients.
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Background: Several trials evaluated the role of ovarian function suppression for the adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer. Based on the results of the SOFT and TEXT trials, international guidelines recommend the addition of ovarian function suppression to standard adjuvant endocrine...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
: A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as highly effective treatments for solid tumours. ADCs conjugate conventional chemotherapeutics with highly selective targeted monoclonal antibodies. Anti-HER2 therapies selectively target cancer cells expressing human epidermal growth factor receptor 2 (HER2),...
Uploaded on: February 11, 2024 -
2023 (v1)Publication
: Endocrine therapy is one of the standard adjuvant treatments to reduce the risk of recurrence and mortality in patients with hormone receptor positive early breast cancer. Despite its proven efficacy, ET side effects, which persist over time even if low grade, may deteriorate quality of life. During follow-up visits, emphasis is generally...
Uploaded on: January 31, 2024 -
2024 (v1)Publication
Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clinical complexities, determining the optimal sequence of HER2-targeted therapies remains partly...
Uploaded on: July 6, 2024 -
2018 (v1)Publication
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Cyclin-dependent kinases (CDK) 4/6 inhibitors, namely abemaciclib, palbociclib, and ribociclib, interfere with cell cycle progression, induce cell senescence and might promote cancer cell disruption by a cytotoxic T cells-mediated effect. Phase III randomized clinical trials have proven that CDK4/6 inhibitors (CDK4/6i) in combination with...
Uploaded on: April 14, 2023 -
2024 (v1)Publication
: Antibody-drug conjugates (ADCs) represent a novel class of molecules composed of a recombinant monoclonal antibody targeted to a specific cell surface antigen, conjugated to a cytotoxic agent through a cleavable or non-cleavable synthetic linker. The rationale behind the development of ADCs is to overcome the limitations of conventional...
Uploaded on: February 14, 2024 -
2018 (v1)Publication
Background: The optimal strategy for monitoring metastatic breast cancer (M-MBC) is unclear. Nevertheless, M-MBC influences patient's quality of life and it affects the use of resources in terms of both drugs and diagnostic exam prescription. We aim to disclose oncologists' approach on M-MBC, identifying controversial areas. Methods: An...
Uploaded on: March 27, 2023 -
2017 (v1)Publication
This was a multicenter retrospective cohort study comparing the patterns of care and clinical outcomes of 416 HER2-positive metastatic breast cancer patients with de novo or recurrent disease undergoing first-line trastuzumab-based therapy. Patients with de novo disease showed significantly better survival outcomes than those with recurrent...
Uploaded on: March 27, 2023 -
2022 (v1)Publication
: Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in hormone receptor positive (HR+) breast cancer (BC). Thus, endocrine therapy (ET) alone or in combination with targeted agents constitutes the mainstay of the treatment for this BC subtype. Despite its efficacy, intrinsic or acquired resistance to ET...
Uploaded on: February 22, 2023 -
2018 (v1)Publication
Background Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. Methods: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter Italian GIM14/BIOMETA study were retrieved....
Uploaded on: January 31, 2024 -
2020 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) increases surgical and conservative surgery chances. However, a significant proportion of patients will not be eligible for conservative surgery following NACT because of large tumor size and/or low chemosensitivity, especially for hormone receptor (HR)-positive/ human epidermal growth...
Uploaded on: February 4, 2024 -
2022 (v1)Publication
The treatment of HR+/HER2- metastatic breast cancer with cyclin-dependent kinases 4 and 6 inhibitors combined with endocrine therapy has recently emerged as the most relevant therapeutic strategy. However, in routine clinical practice, the best therapeutic approach in patients with comorbidities at early relapsing or ab initio metastatic...
Uploaded on: February 11, 2024